for 48 hours. Eradication was defined as below the limit of detection. Definitions include:

- Sensitive (S) if 3-log decrease in bacterial density or eradication at any time point.
- Weakly Sensitive (WS) with 1- to 3-log decrease and Resistant (R) with no decrease.

**Results.**

Based on BL alone, (n = 19), 68% strains were S, 32% were resistant. BL + R (10 μg/mL) effect in 25% (n = 3) and exerted a protective effect against 33% (n = 4). BL + F (1 μg/mL) potentiated in 67%. BL + D (0.1–1.5 μg/mL) in 83% of strains tested. The most resistant strain was eradicated using BL + D at an increased concentration of demeclocycline (2.5 μg/mL).

**Conclusion.**

F and D enhanced the potential for eradication compared with BL exposure alone. R was a photo-protectant to BL for select strains. Prior studies have hypothesized endogenous intracellular porphyrins excited by BL causing energy transfer and production of highly cytotoxic reactive oxygen species causing bacterial death. Future clinical research evaluating the use of preoperative FS and surgical site exposure to BL as a preventative PJI strategy are needed. Our research showed with the addition of PS significantly reduces the bacterial burden of clinically relevant PJI shoulder isolates of C. acnes in an in vitro model.

**Disclosures.** All authors: No reported disclosures.

---

**387. A Rare Manifestation of a Common Disease: Tenosynovitis Associated with C. difficile**

**Case Report and Review of Literature**

Greta M. Josephson, DO1 and Sara R. Aejio, MD2.

1University of Illinois at Chicago / Advocate Christ Medical Center, Chicago, Illinois; 2Advocate Christ Medical Center, Oak Lawn, Illinois

**Session:** 48. Infections of Joints

**Thursday, October 3, 2019: 12:15 PM**

**Background.** Reactive arthritis typically develops following enteric or genital-urinary infection. The most common offending pathogens are Chlamydia, Salmonella, Shigella, Campylobacter and Yersinia. We report a unique case of a patient with tenosynovitis attributed to Clostridium difficile (C. difficile), and review of the literature.

**Methods.** We searched PubMed for “reactive arthritis” and “C. difficile” and found 53 cases. Two additional cases were excluded as they were published in French.

**Results.** An 18-year-old healthy male presented with nine days of abdominal pain and diarrhea, and two days of pain and swelling of bilateral fingers with an erythematous/erythematous rash over the second and third fingers. Four weeks prior to symptom onset he received antibiotics for streptococcal pharyngitis. On presentation he had diffuse paraspinal pain and edema in the right shoulder, with tenderness throughout the phalangeal soft tissue, consistent with tenosynovitis. He had a leukocyte count of 33.0 thousand/μL and C-reactive protein of 12.0 mg/dL (normal < 1.0 mg/dL). C. difficile toxin PCR was positive, toxin EIA was negative. CT scan of the abdomen and pelvis demonstrated mural thickening consistent with extensive severe colitis. He received 14 days of oral vancomycin, with complete symptom resolution, including the tenosynovitis. Our literature review revealed 22.6% (12/53) of cases had involvement of hands, although all also had involvement of other joints. Our patient’s isolated tenosynovitis of bilateral hands is unique, and has only been reported once prior to our knowledge. Literature suggests treatment of the underlying pathogen is considered in such cases.

**Conclusion.** C. difficile continues to pose a significant threat to health and burden on the healthcare system. The association of reactive arthritis and C. difficile was first reported in 1976, with only 53 subsequent cases reported. Reactive arthritis classically presents as asymmetrical oligo- or polyarthritis involving lower extremities. It is imperative that this relationship be considered and treatment failure of conservative strategies.

**Disclosures.** All authors: No reported disclosures.

---

**388. Spinal Implant Infections Treated with Debridement and Hardware Retention**

Cynthia Jihan, MD1; Santiago Martínez, Degree2; Orlando Pardo, Nurse3; Cintia C. Vila, Fuego4; Segundo Martinez, MD1; Juan Ignacio Dugas, MD1 and Andrea Vila, MD1; Hospital Italiano de Mendoza, Mendoza, Argentina; 1HEMCONICET, Mendoza, Argentina

**Session:** 48. Infections of Joints

**Thursday, October 3, 2019: 12:15 PM**

**Background.** Surgical site infections following spinal surgery affect 0.3 to 20% of patients. The longer the infection, the greater the chance of antibiotic treatment failure due to the establishment of mature microbial biofilm on the hardware, requiring its removal for infection eradication.

**Methods.** Retrospective cohort of patients with microbiologically confirmed SII following spinal surgery treated with debridement and retention. SII was defined as the presence of clinical signs of deep surgical site infection with 2 or more positive culture results of tissue surrounding the implant taken during surgical debridement; or from CT guided biopsy. Inclusion criteria: adults with a 1º episode of microbiological confirmed SII diagnosed from 2008 to 2017 with >2 years of follow-up, treated with implant retention. Definitions: Early-onset infection (EOI): infection <1 month following implant placement; Late-onset infection (LOI); between 30 days and 1 year after implant placement. Delayed onset infection (DOI): >1 year of implant placement. Statistical analysis made in GraphPad Prism 5.0.

**Results.** We analyzed 19 patients with SII treated with hardware retention. Mean age was 54 years (21–70) years, 63% were female. Comorbidities, clinical manifestations and motive for surgery are in Table 1 and Figure 2. Hardware material used was titanium (57%) and steel (24%). In addition to the hardware,11 patients (57.9%) underwent bone grafting, 4 experienced treatment failure (4/11 = 36.4%); 2 patients had nonmetallic material inserted (carbon polymer), the 2 patients experienced failure. 16 patients (84.2%) had EOI, 2 (10.5%) LOI, 1 (5.3%) DOI. Failure requiring implant removal was observed in 26.3% (n = 5), 2 of the cases were EOI, 2 LOI and 1 DOI. Bacterial characteristics of patients are shown in Table 2. 47.4% of patients required more than one debridement (Figure 2). In the linear regression model, treatment failure was associated with bone grafting (P = 0.04) and the use of carbon polymer materials (P = 0.007).

**Conclusion.** Treatment of SII with debridement plus antimicrobials treatment is acceptable, with a rate failure of 26%. In LOI and DOI spinal implant retention is more prone to failure. Bone grafting and the presence of polymers seem to be associated with treatment failure of conservative strategies.

**Table 1. Comorbidities**

| Characteristics       | Value |
|-----------------------|-------|
| Diabetes              | 4/21.1% |
| Smoking               | 2/10.5% |
| Liver Diseases        | 0      |
| Steroid use           | 2/10.5% |
| Hypothyroidism        | 2/10.5% |
| Immunosuppressive therapy | 3/16.8% |
| Systemic malignancy   | 4/21.1% |
| Haematological malignancy | 2/10.5% |
| Radiotherapy          | 1/5.3% |
| ASA score 1-2         | 11/57.9% |
| ASA score 3-4         | 6/42.1% |

**Table 2. Bacterial characteristics of patients with spinal implant infection included in the study (n = 19)**

| Pathogen                  | n (%) |
|---------------------------|-------|
| MSSA                      | 4/21.1% |
| MRCONS                    | 2/10.5% |
| MRCONS                    | 3/15.8% |
| Enterococcus spp.         | 2/10.5% |
| Escherichia coli          | 1/5.3% |
| Proteus spp.              | 1/5.3% |
| Sneathiopseudomonas multihaemolytica | 1/5.3% |
| Chriobacter rodentium     | 1/5.3% |
| Enterobacter spp.         | 1/5.3% |
| Polymicrobial             | 1/5.3% |
| MRCONS + MRCONS           | 3/15.8% |
| MRCONS + Streptococcus spp. | 3/15.3% |
| MRCONS + Enterococcus faecium | 1/5.3% |
| Lute                      | 0      |
| MSSA                      | 2/10.5% |
| Polysaccharide spp.       | 1/5.3% |

**Figure 1.**

**Figure 2.**

**Number of debridement surgery**

- Once
- Twice
- 3 and more

**Disclosures.** All authors: No reported disclosures.